Shares of Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) have been assigned an average recommendation of “Buy” from the seven analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $16.50.

RNN has been the subject of several analyst reports. Seaport Global Securities reiterated a “buy” rating and set a $13.00 price objective on shares of Rexahn Pharmaceuticals in a report on Friday, October 6th. Zacks Investment Research upgraded Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a report on Wednesday, October 4th. HC Wainwright reiterated a “buy” rating and set a $19.50 price objective on shares of Rexahn Pharmaceuticals in a report on Monday, November 6th. Finally, ValuEngine upgraded Rexahn Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, November 2nd.

Shares of Rexahn Pharmaceuticals (RNN) opened at $2.12 on Friday. Rexahn Pharmaceuticals has a twelve month low of $0.38 and a twelve month high of $7.10. The company has a market capitalization of $67.24, a price-to-earnings ratio of -2.28 and a beta of -0.66.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RNN. Susquehanna International Group LLP acquired a new position in shares of Rexahn Pharmaceuticals in the 2nd quarter valued at $2,905,000. Sabby Management LLC acquired a new stake in Rexahn Pharmaceuticals during the 2nd quarter worth about $706,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Rexahn Pharmaceuticals during the 3rd quarter worth about $119,000.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/01/14/rexahn-pharmaceuticals-inc-rnn-given-consensus-rating-of-buy-by-brokerages-2.html.

About Rexahn Pharmaceuticals

Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.

Analyst Recommendations for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.